# US 2023/0398094 A1 · Method of treating expressive language deficit in autistic humans

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0398094 A1
- Document ID: US20230398094A1
- Status: Published application
- Kind: A1
- Application number: 17/838,192
- Filed: 2022-06-11
- Published: 2023-12-14
- Earliest claimed: 2022-06-11
- Assignees: AMS Therapeutics, LLC
- Inventors: Charles E. Niesen
- Web page: https://patentgrep.com/patent/US20230398094A1

## CPC

- A61K 31/4015: having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmacological method for treating the expressive language deficit in an autistic human child or adult is provided. A therapeutically effective dose of a succinimide anticonvulsant, e.g., ethosuximide, methsuximide, phensuximide, or a pharmaceutically acceptable salt thereof, is administered to a patient suffering from expressive language deficit, preferably over an extended period, e.g., six months or longer. Language gains are retained even after treatment is discontinued.

## Claims

### Claim 1

A method of treating expressive language deficit in an autistic human, comprising:
administering ethosuximide to an autistic human at a dosage and for a period of time sufficient to reduce the autistic human's expressive language deficit.

### Claim 2 (depends on 1)

The method of claim 1, wherein the dosage is 10-60 mg/kg/day.

### Claim 3 (depends on 1)

The method of claim 1, wherein the dosage is 20-40 mg/kg/day.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage is 150-1000 mg b.i.d.

### Claim 5 (depends on 3)

The method of claim 3, wherein the dosage is 150-500 mg b.i.d.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage is 500-1000 mg b.i.d.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ethosuximide is administered twice per day.

### Claim 8 (depends on 1)

The method of claim 1, wherein the ethosuximide is administered daily for at least six months.

### Claim 9 (depends on 1)

The method of claim 1, wherein the ethosuximide is administered orally.

### Claim at position 10

10-12. (canceled)

### Claim 13

A method of improving expressive language skills in an autistic human, comprising:
administering ethosuximide to an autistic human at a dosage and for a period of time sufficient to raise the autistic human's expressive language skills by at least 1 point on a 7-point scale, where 0=non-verbal, 1=echolalic, 2=single words, 3=phrases, 4=sentences, 5=spontaneous speech, and 6=mutual speech (true conversation with another person).

### Claim 14 (depends on 13)

The method of claim 13, wherein the ethosuximide is administered for a period of time sufficient to raise the autistic human's expressive language skills by at least 1.5 points.

### Claim 15 (depends on 13)

The method of claim 13, wherein the ethosuximide is administered for a period of time sufficient to raise the autistic human's expressive language skills by at least 2 points.

### Claim 16 (depends on 13)

The method of claim 13, wherein the dosage is 150-500 mg b.i.d.

### Claim 17 (depends on 13)

The method of claim 13, Previously presented wherein the dosage is 500-1000 mg b.i.d.

### Claim 18 (depends on 13)

The method of claim 13, where the period of time is at least six months.

### Claim 19 (depends on 13)

The method of claim 13, wherein the autistic human has at least normal IQ.

### Claim 20

A method of treating expressive language deficit in an autistic, nonepileptic human, comprising:
administering ethosuximide to an autistic, nonepileptic human at a dosage and for a period of time sufficient to reduce the autistic, nonepileptic human's expressive language deficit.

### Claim 21 (depends on 20)

The method of claim 20, wherein the dosage is 10-60 mg/kg/day.

### Claim 22 (depends on 20)

The method of claim 20, wherein the period of time is at least six months.

### Claim 23 (depends on 20)

The method of claim 20, wherein the dosage and period of time are sufficient to raise the autistic, nonepileptic human's expressive language skills by at least 1 point on a 7-point scale, where 0=non-verbal, 1=echolalic, 2=single words, 3=phrases, 4=sentences, 5=spontaneous speech, and 6=mutual speech (true conversation with another person).
